Ra Pharmaceuticals, Inc.
(NASDAQ : RARX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
0.72%43.520.9%$1077.96m
MRKMerck & Co., Inc.
1.71%76.120.6%$1076.05m
JNJJohnson & Johnson
1.07%146.050.6%$1047.60m
ABBVAbbVie, Inc.
1.54%91.532.2%$776.01m
BMYBristol-Myers Squibb Company
1.56%54.101.4%$576.54m
LLYEli Lilly and Company
1.48%113.861.0%$520.54m
NVSNovartis AG Sponsored ADR
0.62%87.780.2%$283.94m
AZNAstraZeneca PLC Sponsored ADR
-1.76%40.671.3%$206.04m
GSKGlaxoSmithKline plc Sponsored ADR
-0.15%40.350.2%$131.34m
SNYSanofi Sponsored ADR
1.28%45.140.2%$67.97m
NVONovo Nordisk A/S Sponsored ADR Class B
1.39%44.180.1%$62.57m
LCILannett Company, Inc.
3.82%5.9837.0%$11.05m
AKTXAkari Therapeutics Plc Sponsored ADR
2.28%1.751.7%$0.05m
EPIXESSA Pharma Inc
-1.43%3.000.1%$0.01m

Company Profile

Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of peptide-based drugs for a variety of therapeutic uses. The firm's lead product, RA101495 SC, which is an injection into the tissue under the skin, for the treatment of paroxysmal nocturnal hemoglobinuria. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA.